CareBare Rx Tirzepatide Review

CareBare Rx—found at carebarerx.com—is a multi-vertical telehealth service covering weight loss, hair loss, sexual health, and NAD+ therapy under a "self-care with pride" banner. Our research found a broad GLP-1 lineup with both compounded and brand-name pathways and some uncommon accessibility positives, alongside several transparency gaps to resolve before you enroll.

The GLP-1 Lineup

CareBare Rx's weight loss menu is broader than most newer telehealth services:

• Compounded semaglutide injection—weight loss treatments start at $199/month
• Compounded tirzepatide injection
• Oral semaglutide (the site references Rybelsus®) and oral tirzepatide—injection-free options
• Brand-name Ozempic®—from $749/month, for those who want the FDA-approved finished product

Offering a brand-name pathway alongside compounded options is a meaningful plus: it gives patients who can afford it a route to the FDA-approved product through the same intake. Note, though, that per-medication dosage-tier pricing isn't published—beyond the "starting at" figures, you learn exact costs at intake.

Beyond Weight Loss

The same intake model covers clinically backed oral hair-loss medications (from $99/month), fast-acting and daily ED treatments (from $99/month), and NAD+ therapy (from $199/month). Every plan includes the telemedicine visit and prescription, with free 1-2 day discreet shipping, no insurance required, and FSA/HSA payment eligibility.

Accessibility Positives

Two things stood out in our research. First, intake reviews are fast—licensed providers review your medical intake form within 24 hours. Second, CareBare Rx advertises Spanish-speaking providers ("Médicos que hablan español disponibles"), a genuine accessibility feature that very few telehealth weight loss services offer. The site also displays GLP-1 safety warnings—including the thyroid C-cell tumor boxed-warning context and MTC/MEN 2 contraindications—more prominently than many competitors, and states plainly that compounded medication "is not evaluated by the FDA for safety or effectiveness."

What to Confirm

CareBare Rx names its providers only partially—"Dr. Powers" and "Dr. Italia" appear without first names, credentials, or specialties—and the site publishes no legal entity name, physical address, phone number, or direct email (contact is via a web form). Partner pharmacies are not named, states served are not listed, and we could not find a refund or cancellation policy on the main pages. The site displays a LegitScript badge, which we recommend confirming directly in LegitScript's certification checker. Before enrolling, ask for the prescribing provider's full name and license, the dispensing pharmacy, your exact ongoing monthly price, and the cancellation terms in writing.

Critical 2026 Regulatory Context

In 2026 the FDA proposed excluding semaglutide and tirzepatide from the 503B bulks list, restricting mass GLP-1 compounding. Confirm current availability of the compounded options—and how the brand-name pathway is priced—before enrolling.

Important: Compounded Medications

Compounded medications are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality—which CareBare Rx itself states. Use only under medical supervision.